Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.67.
Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a research note on Thursday. JPMorgan Chase & Co. raised Solid Biosciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $15.00 in a research note on Monday, July 15th. Barclays dropped their price target on Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Finally, William Blair raised Solid Biosciences to a “strong-buy” rating in a research note on Friday, August 30th.
View Our Latest Research Report on SLDB
Institutional Investors Weigh In On Solid Biosciences
Solid Biosciences Stock Performance
Shares of NASDAQ SLDB opened at $5.77 on Friday. The stock has a market cap of $222.72 million, a PE ratio of -1.75 and a beta of 1.92. Solid Biosciences has a fifty-two week low of $2.00 and a fifty-two week high of $15.05. The stock has a fifty day moving average of $6.91 and a 200-day moving average of $7.78.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.12). On average, sell-side analysts predict that Solid Biosciences will post -2.61 EPS for the current year.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Articles
- Five stocks we like better than Solid Biosciences
- What is Put Option Volume?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.